Onk Therapeutics Ltd.

Fate’s pipeline reprioritization raises questions about iPSC-derived NK cells

Plus: Moore to head Roche Diagnostics North America division, and updates from Agios, Verge, LifeMine and more

Plus updates from Atara, Moderna, Regeneron, Agios, GSK, BioMarin, Bayer, Intellia-ONK, Merck KGaA, Blue Water

Plus: NCI licenses for Neogene, Sana and updates from Allogene-Antion, Illumina bluebird, ONK, Gameto

Emerging Company Profile: Ireland’s ONK Therapeutics soups up CAR NK cells with TRAIL variants

Lowell Schiller left FDA to join Aetion Inc. as chief legal and regulatory officer.  For nearly the past two years, Schiller was principal associate commissioner for policy, serving briefly

Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the